Vertex Casgevy Sales Jump 219% to $54M in Q4, Hits $116M for 2025
Vertex Pharmaceuticals recorded $54M in Casgevy sales in Q4, a 219% increase from $16.9M in Q3, driving full-year 2025 revenues of $116M. Patient initiations and first cell collections tripled year over year, underpinning the therapy’s growth and collaboration profit-sharing expected to bolster Vertex’s pipeline returns.
1. Casgevy Q4 Sales Surge
Vertex recorded $54M in Q4 Casgevy sales, up from $16.9M in Q3, driven by a threefold increase in patient initiations and first cell collections compared with the prior quarter.
2. Full-Year Casgevy Performance
The therapy generated $116M in full-year 2025 revenues, reflecting accelerated commercialization and improved reimbursement access across major markets.
3. Collaboration and Future Outlook
Under a 60:40 profit-and-cost-sharing agreement with its partner, rising Casgevy revenues are poised to enhance Vertex’s pipeline returns, with label-expansion regulatory submissions planned in the first half of 2026.